Vijoice
What Vijoice is used for
Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Vijoice
- Active substance
- alpelisib
- Disease area
- Genetic Diseases, Inborn; Growth Disorders
- Medicine group
- Antineoplastic agents
- ATC code
- L01EM03
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2026
Official information
In the USA
In India
- Alpelisib: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vijoice used for?
Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)
What is the active substance in Vijoice?
Vijoice contains alpelisib.
Who makes Vijoice?
The EU marketing authorisation holder is Novartis Europharm Limited.
Is Vijoice an orphan medicine?
Yes. Vijoice is designated an orphan medicine in the EU, for a rare disease (Genetic Diseases, Inborn; Growth Disorders).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU